Drug Profile
VGX 100
Alternative Names: VGX-100Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Vegenics
- Developer Ceres Oncology; Opthea
- Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders; Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)